Median Duration of Response (DOR)

In 111 female patients with HER2+ unresectable or mBC,

ENHERTU monotherapy demonstrated a durable mDOR of nearly 15 months1,a

14.8 Average duration of response in ENHERTU patients 14.8 Average duration of response in ENHERTU patients

aMedian DOR based on Kaplan-Meier estimate. DOR based on a median duration of follow-up of 11.1 months.1

Ready to learn more about ENHERTU?